Dantron: Difference between revisions

	WikiDoc Resources for Dantron
Articles
Most recent articles on Dantron Most cited articles on Dantron Review articles on Dantron Articles on Dantron in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Dantron Images of Dantron Photos of Dantron Podcasts & MP3s on Dantron Videos on Dantron
Evidence Based Medicine
Cochrane Collaboration on Dantron Bandolier on Dantron TRIP on Dantron
Clinical Trials
Ongoing Trials on Dantron at Clinical Trials.gov Trial results on Dantron Clinical Trials on Dantron at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Dantron NICE Guidance on Dantron NHS PRODIGY Guidance FDA on Dantron CDC on Dantron
Books
Books on Dantron
News
Dantron in the news Be alerted to news on Dantron News trends on Dantron
Commentary
Blogs on Dantron
Definitions
Definitions of Dantron
Patient Resources / Community
Patient resources on Dantron Discussion groups on Dantron Patient Handouts on Dantron Directions to Hospitals Treating Dantron Risk calculators and risk factors for Dantron
Healthcare Provider Resources
Symptoms of Dantron Causes & Risk Factors for Dantron Diagnostic studies for Dantron Treatment of Dantron
Continuing Medical Education (CME)
CME Programs on Dantron
International
Dantron en Espanol Dantron en Francais
Business
Dantron in the Marketplace Patents on Dantron
Experimental / Informatics
List of terms related to Dantron

Dantron
	File:Dantron.svg
Clinical data
Routes of; administration	Oral, rectal (enema)
ATC code	A06AB03 (WHO) A06AG03 (WHO);
Identifiers
	IUPAC name 1,8-dihydroxyanthracene-9,10-dione;
CAS Number	117-10-2 ;
PubChem CID	2950;
DrugBank	DB04816 ;
ChemSpider	2845 ;
UNII	Z4XE6IBF3V;
KEGG	D07107 ;
ChEBI	CHEBI:3682 ;
ChEMBL	ChEMBL53418 ;
NIAID ChemDB	001375;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C14H8O4
Molar mass	240.211 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C2c1cccc(O)c1C(=O)c3c2cccc3O;
	InChI InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H ; Key:QBPFLULOKWLNNW-UHFFFAOYSA-N ;
(what is this?) (verify)

VisualWikitext

Revision as of 18:38, 10 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Dantron (INN), also known as chrysazin or 1,8-dihydroxyanthraquinone, is an organic substance, formally derived from anthraquinone by the replacement of two hydrogen atoms by hydroxyl groups (–OH). It is used in some countries as a stimulant laxative.

It should not be confused with ondansetron, an unrelated drug that was marketed in South Africa under the trade name "Dantron".

Medical uses

In the USA, dantron is not used because it is considered to be a carcinogen.^[1]

In the UK it is considered a possible carcinogen and so its licence is restricted to patients who already have a diagnosis of terminal cancer. It is mainly used in palliative care to counteract the constipating effects of opioids. Its British Approved Name was danthron, but it has now been changed to "dantron", the recommended International Nonproprietary Name.^[2]

Dantron has the notable side-effect of causing red-colored urine.

References

↑ Danthron substance profile at the National Toxicology Program website
↑ British National Formulary website (requires free registration)

Template:Laxatives

[1] Danthron substance profile at the National Toxicology Program website

[BNF-2] British National Formulary website (requires free registration)

[1]

[2]

@@ Line 1: / Line 1: @@
 {{Drugbox
-| IUPAC_name        = 1,8-dihydroxyanthracene-9,10-dione
+| Verifiedfields = changed
-| image             = Dantron.svg
+| Watchedfields = changed
-| CAS_number        = 117-10-2
+| verifiedrevid = 322159605
-| ATC_prefix        = A06
+| IUPAC_name = 1,8-dihydroxyanthracene-9,10-dione
-| ATC_suffix        = AB03
+| image = Dantron.svg
-| ATC_supplemental  = {{ATC|A06|AB53}} {{ATC|A06|AG03}}
+| image2 = 1,8-Dihydroxyanthraquinone-3D-balls.png
-| PubChem           = 2950
-| DrugBank          =
+<!--Clinical data-->
-| C=14|H=8|O=4
+| tradename =
-| molecular_weight  = 240.211 g/mol
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
-| bioavailability   =
+| pregnancy_US = <!-- A / B            / C / D / X -->
-| protein_bound     =
+| pregnancy_category =
-| metabolism        =
+| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
-| elimination_half-life =
+| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
-| excretion         =
+| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
-| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
+| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
-| pregnancy_US      =  <!-- A / B            / C / D / X -->
+| legal_status =
-| pregnancy_category=
-| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
-| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
-| legal_UK          =  <!-- GSL         / P       / POM / CD / Class A, B, C -->
-| legal_US          =  <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
-| legal_status      =
 | routes_of_administration = Oral, rectal ([[enema]])
+<!--Pharmacokinetic data-->
+| bioavailability =
+| protein_bound =
+| metabolism =
+| elimination_half-life =
+| excretion =
+<!--Identifiers-->
+| CASNo_Ref = {{cascite|correct|CAS}}
+| CAS_number_Ref = {{cascite|correct|??}}
+| CAS_number = 117-10-2
+| ATC_prefix = A06
+| ATC_suffix = AB03
+| ATC_supplemental = {{ATC|A06|AG03}}
+| PubChem = 2950
+| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
+| DrugBank = DB04816
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = 2845
+| NIAID_ChemDB = 001375
+| UNII_Ref = {{fdacite|changed|FDA}}
+| UNII = Z4XE6IBF3V
+| KEGG_Ref = {{keggcite|changed|kegg}}
+| KEGG = D07107
+| ChEBI_Ref = {{ebicite|changed|EBI}}
+| ChEBI = 3682
+| ChEMBL_Ref = {{ebicite|changed|EBI}}
+| ChEMBL = 53418
+<!--Chemical data-->
+| C=14 | H=8 | O=4
+| molecular_weight = 240.211 g/mol
+| smiles = O=C2c1cccc(O)c1C(=O)c3c2cccc3O
+| InChI = 1/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H
+| InChIKey = QBPFLULOKWLNNW-UHFFFAOYAR
+| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
+| StdInChI = 1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H
+| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
+| StdInChIKey = QBPFLULOKWLNNW-UHFFFAOYSA-N
 }}
+__NOTOC__
 {{SI}}
+{{CMG}}
+==Overview==
+'''Dantron''' ([[International Nonproprietary Name|INN]]), also known as '''chrysazin''' or '''1,8-dihydroxyanthraquinone''', is an [[organic substance]], formally derived from [[anthraquinone]] by the replacement of two [[hydrogen]] atoms by [[hydroxyl]] [[functional group|groups]] (–OH).  It is used in some countries as a stimulant [[laxative]].
+It should not be confused with [[ondansetron]], an unrelated drug that was marketed in [[South Africa]] under the [[trade name]] "Dantron".
+==Medical uses==
+In the [[United States|USA]], dantron is not used because it is considered to be a carcinogen.<ref>[http://ntp.niehs.nih.gov/ntp/roc/eleventh/profiles/s055dant.pdf Danthron substance profile] at the [[National Toxicology Program]] website</ref>
-==Overview==
+In the [[United Kingdom|UK]] it is considered a possible carcinogen and so its licence is restricted to patients who already have a diagnosis of terminal cancer. It is mainly used in [[palliative care]] to counteract the constipating effects of [[opioids]]. Its  [[British Approved Name]] was '''danthron''', but it has now been changed to "dantron", the recommended International Nonproprietary Name.<ref name=BNF>[http://www.bnf.org/ British National Formulary website] (requires free registration)</ref>
-:''"Dantron" is also a [[trade name]] of [[ondansetron]], an unrelated drug, in [[South Africa]].''
-'''Dantron''' (also known as '''chrysazin''') is an [[anthraquinone]] derivative, 1,8-dihydroxyanthraquinone, used in some countries as a stimulant [[laxative]]. In the USA it is considered to be a carcinogen,<ref>[http://ntp.niehs.nih.gov/ntp/roc/eleventh/profiles/s055dant.pdf Danthron substance profile] at the [[National Toxicology Program]] website</ref> and is therefore not used. In the UK it is considered a possible carcinogen and so its licence is restricted to patients who already have a diagnosis of terminal cancer (i.e. it is mainly used in [[palliative care]] to counteract the constipating effects of [[opioids]])
-It has the notable side-effect of causing red-coloured urine.
+Dantron has the notable side-effect of causing red-colored urine.
-"Danthron" was the [[British Approved Name]], but it has now been changed to "dantron" in harmony with the recommended [[International Nonproprietary Name]] (rINN).<!--The link returns an error [http://www.bnf.org/bnf/bnf/52/63581.htm?q=%22danthron%22#_hit] (British National Formulary site - requires free registration) -->
+==See also==
+* [[Hydroxyanthraquinone]]
+* [[Rhein (molecule)]]
 ==References==
-<references/>
+{{reflist|2}}
 {{Laxatives}}
@@ Line 43: / Line 88: @@
 [[Category:IARC Group 2B carcinogens]]
 [[Category:Laxatives]]
-{{WH}}
+[[Category:Dihydroxyanthraquinones]]
-{{WikiDoc Sources}}
+[[Category:Drug]]

Clinical data
File:Dantron.svg

Routes of administration	Oral, rectal (enema)
ATC code	A06AB03 (WHO) A06AG03 (WHO)
Identifiers
IUPAC name 1,8-dihydroxyanthracene-9,10-dione
CAS Number	117-10-2^Y
PubChem CID	2950
DrugBank	DB04816^N
ChemSpider	2845^Y
UNII	Z4XE6IBF3V
KEGG	D07107^N
ChEBI	CHEBI:3682^N
ChEMBL	ChEMBL53418^N
NIAID ChemDB	001375
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₄H₈O₄
Molar mass	240.211 g/mol
3D model (JSmol)	Interactive image
SMILES O=C2c1cccc(O)c1C(=O)c3c2cccc3O
InChI InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H^N Key:QBPFLULOKWLNNW-UHFFFAOYSA-N^N
^NY (what is this?) (verify)

Dantron: Difference between revisions

Revision as of 18:38, 10 April 2015

Overview

Medical uses

See also

References

Navigation menu